Trial Profile
An open-label, prospective, randomized study of the effect of PEGASYS [peginterferon alfa-2a] plus ribavirin, with or without amantadine, on sustained virological response in patients with chronic hepatitis C viral infection who either did not respond or relapsed after prior treatment with interferon plus ribavirin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Jun 2010
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Amantadine
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 08 Jun 2006 New trial record.